Octreotide therapy for the Sjögren syndrome [5]

Annals of Internal Medicine

Volumn 137, Issue 9, 2002, Pages 777-778

  Phan, Tri G ^a   Gordon, Tom P ^a   Tattersall, Martin H N ^a   Loblay, Robert H ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE;

AGED; ANAMNESIS; CASE REPORT; CLINICAL EXAMINATION; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LETTER; PRIORITY JOURNAL; SJOEGREN SYNDROME; TREATMENT OUTCOME;

EID: 0037027463     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-137-9-200211050-00031     Document Type: Letter

References (5)

1. Fox RI, Stern M, Michelson P. Update in Sjögren syndrome. Curr Opin Rheumatol. 2000;12:391-8. [PMID: 10990175]
2. Lichtenauer-Kaligis EG, van Hagen PM, Lamberts SW, Hofland LJ. Somatostatin receptor subtypes in human immune cells. Eur J Endocrinol. 2000;143 Suppl 1:S21-5. [PMID: 11068936]
3. van Hagen PM. Somatostatin receptor expression in clinical immunology. Metabolism. 1996;45:86-7. [PMID: 8769392]
4. Paran D, Elkayam O, Mayo A, Paran H, Amit M, Yaron M, et al. A pilot study of a long acting somatostatin analogue for the treatment of refractory rheumatoid arthritis. Ann Rheum Dis. 2001;60:888-91. [PMID: 11502617]
5. ten Bokum AM, Hofland LJ, de Jong G, Bouma J, Melief MJ, Kwekkeboom DJ, et al. Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas. Eur J Clin Invest. 1999;29:630-6. [PMID: 10411670]